ArticleJournal of ophthalmic inflammation and infection2025
Tubulointerstitial nephritis and uveitis (TINU) syndrome: a case series.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Noninfectious uveitis in childhood : Clinical aspects, diagnostics, treatment and transition].Die Ophthalmologie · 2026Review
- Tubulointerstitial nephritis and uveitis syndrome in a patient with diabetic nephropathy: a case report and literature review.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTubulointerstitial nephritis and uveitis (TINU) syndrome, characterised by the co-occurrence of tubulointerstitial nephritis and uveitis in the absence of other systemic diseases, presents a diagnostic challenge due to its non-specific symptoms. This case series aims to shed light on TINU syndrome's clinical features, underlying causes, and management strategies. The prevalence of TINU syndrome is relatively low with estimates of 3.5 cases/ million people with an incidence of 0.2 cases/ million/ year and it often goes underdiagnosed. The ratio of males to females reported was 4:1. Histological confirmation through renal biopsy is crucial, while systemic conditions such as systemic lupus erythematosus, tuberculosis, sarcoidosis, and Sjogren's disease should be excluded. In most cases, TINU appears to be an idiopathic immune-mediated process, but it may be precipitated by drugs or infections. Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with some cases of TINU syndrome. Genetic markers, particularly HLA subtypes, have shown a strong association with TINU syndrome. Uveitis which is characterised by intraocular inflammation is a common feature of TINU syndrome. Anterior uveitis, the most prevalent form, presents with symptoms such as red eye, eye pain, photophobia, and keratic precipitates which are subdivided into granulomatous and non-granulomatous. Corticosteroids represent the primary treatment for ocular inflammation, while immunosuppressant medications may be employed for treatment of nephritis. OBSERVATIONS: Through the analysis of five TINU syndrome cases, this case series provides insights into the clinical presentations, laboratory findings, and biopsy results of patients with TINU syndrome. The cases include individuals with associated systemic conditions such as asthma, psoriasis and hyperthyroidism. CONCLUSION AND IMPORTANCE: In conclusion, TINU syndrome is a rare condition characterised by the simultaneous occurrence of tubulointerstitial nephritis and uveitis. Increased awareness among healthcare professionals is necessary for early recognition and appropriate management of this syndrome. Further research is needed to elucidate the pathogenesis, optimise diagnostic criteria, and explore more targeted therapeutic approaches for TINU syndrome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.